Breastfeeding
The US Centers for Disease Control and Prevention (CDC) recommends that HIV-infected mothers do not breastfeed their infants to avoid risking postnatal transmission of HIV. This recommendation is coupled with the potential for serious adverse reactions in nursing infants. Dolutegravir and abacavir were shown to be excreted in the milk of lactating rats. Lamivudine was shown to be excreted in human breast milk. History
Approval
The patent was filed on April 28, 2006, and expires on October 5, 2027. It was approved for use in the United States and in the European Union in 2014. Major label changes
In August 2015, the Food and Drug Administration (FDA) sent a bulletin regarding label updates for dolutegravir and Triumeq regarding drug-drug information.Drug interactions was updated to include a statement that in vitro, dolutegravir was not a substrate of OATP1B1 or OATP1B3.
Abacavir/dolutegravir/lamivudine, sold under the brand name Triumeq among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. It is a combination of three medications with different and complementary mechanisms of action: abacavir (reverse transcriptase inhibitor), dolutegravir (integrase inhibitor) and lamivudine (nucleoside analog reverse transcriptase inhibitor).The medication was developed by ViiV Healthcare and was approved for use in the United States and in the European Union in 2014.Abacavir is a nucleotide reverse transcriptase inhibitor. Specifically, abacavir is a guanosine analogue that interferes with HIV viral RNA-dependent DNA polymerase, ultimately resulting in inhibition of replication of HIV. Dolutegravir inhibits the HIV replication cycle by binding to the integrase active site and inhibiting the strand transfer step of HIV-1 DNA integration. Lamivudine is a cytosine analogue that inhibits HIV reverse transcription by terminating the viral DNA chain. Medical uses
Abacavir/dolutegravir/lamivudine is indicated for the treatment of HIV/AIDS in adults and adolescents aged 12 years of age and older who weigh at least 40 kilograms (88 lb). Adverse effects
The following adverse reactions were reported in <2% of patients:
Central nervous system: drowsiness, lethargy, nightmares, sleep disorders, suicidal ideation
Dermatologic: pruritus
Endocrine and metabolic: high levels of triglycerides
Gastrointestinal: abdominal distention, abdominal distress, abdominal pain, lack of appetite, stomach upset, flatulence, gastroesophageal reflux disease, upper abdominal pain, vomiting
Hepatic: hepatitis
Neuromuscular and skeletal: joint pain, muscle inflammation
Kidney: chronic kidney disease
Miscellaneous: feverSee individual agents as well as other combination products for additional information. Pregnancy
Abacavir/dolutegravir/lamivudine should only be used in pregnancy if the potential benefits outweigh the risks.